824433bf-151c-46ea-9ea7-f53813f66a97
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.400
- TGF_BETA_SIGNALING+0.400
- ANGIOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- G2M_CHECKPOINT+0.300
- HEDGEHOG_SIGNALING+0.300
- UV_RESPONSE_DN+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- APICAL_JUNCTION+0.200
- KRAS_SIGNALING_UP+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.600
- CHOLESTEROL_HOMEOSTASIS-0.500
- FATTY_ACID_METABOLISM-0.500
- ADIPOGENESIS-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- MTORC1_SIGNALING-0.400
- MYC_TARGETS_V2-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- BILE_ACID_METABOLISM-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-58-8388-01A-11R-2326-07 | — | cohortSQ1 | 0.888 |
| 2 | a83e78c0-8b1b-4576-aace-4bee1dee5046 | — | — | 0.829 |
| 3 | BS_C41DJZ1F | high-grade glioma | — | 0.829 |
| 4 | TCGA-A7-A26I-01B-06R-A22O-07 | — | D | 0.826 |
| 5 | 0918cbd5-edd0-41c8-8b67-677f35ad4611 | — | — | 0.825 |
| 6 | 20140156.TNBC | — | D | 0.825 |
| 7 | TCGA-64-5779-01A-01R-1628-07 | — | cohortA3 | 0.824 |
| 8 | SRR8518444 | — | D | 0.822 |
| 9 | 1fd89d3a-5991-4bfb-b27f-66b5f2a289d8 | — | — | 0.818 |
| 10 | TCGA-AC-A3QQ-01B-06R-A22O-07 | — | D | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |